2 C
New York
Wednesday, February 1, 2023

Cassava Sciences Inc. (NASDAQ: SAVA) May Be Attracting Institutional Investments

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Cassava Sciences Inc. (SAVA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.39, or -1.32%, to $29.05. The Cassava Sciences Inc. has recorded 69,802 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

Cassava Sciences Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $29.44 and fluctuated between $34.50 as its day high and $27.65 as its day low. The current market capitalization of Cassava Sciences Inc. is $1.17B. A total of 11.83 million shares were traded on the day, compared to an average of 1.27M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, SAVA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 14 BUYs and 6 SELLs from insiders. Insiders purchased 308,319 shares during that period but sold 84,313.

In the most recent transaction, Kupiec James William bought 2,500 shares of SAVA for 24.44 per share on Aug 23. After the transaction, the Chief Clinical Dev. Officer now owns 2,500 company shares. In a previous transaction on Aug 23, Barry Richard bought 36,159 shares at 23.79 per share. SAVA shares that Director owns now total 186,159.

Among the insiders who bought shares, Schoen Eric acquired of 2,500 shares on Aug 12 at a per-share price of $19.95. This resulted in the Chief Financial Officer holding 19,800 shares of SAVA after the transaction. In another insider transaction, ROBERTSON SANFORD bought 100,000 shares at $20.69 per share on Aug 12. Company shares held by the Director now total 1,024,765.


It is more appealing for investors to invest in companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook for the company. SAVA’s most recent ex-dividend date was 12/13/2012 when it declared a $5.25 quarterly dividend that was paid in cash on 12/24/2012.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for SAVA in the last 3 months, the mean price target is $89.33 with high estimates of $124.00 and low estimates of $44.00. In terms of 52-week highs and lows, SAVA has a high of $62.49 and a low of $13.84.

As of this writing, SAVA has an earnings estimate of -$0.48 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.38 per share and a lower estimate of -$0.59. The company reported an EPS of -$0.44 in the last quarter, which was -7.30% lower than expectations of -$0.41.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 3 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SAVA is Buy with a score of 4.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles